secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2022-10-28T23:59:59+00:00
Accession:  0001564590-22-035701
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma Q3 net loss narrows to $2.3M; strategic review with workforce reduction
--------------------------------------------------------------------------------

- Net loss of $2.3M ($0.16/sh) narrowed from $4.7M ($0.33/sh) in Q3 2021.
- Cash $43.9M as of Sep 30, 2022; sufficient to fund operations through end of 2023.
- Workforce reduction with ~$0.8M restructuring charges recorded in Q3 2022.
- Strategic review with Ladenburg Thalmann; evaluating acquisition, merger, or other options.
- R&D expenses fell to $1.0M from $3.4M due to completion of rNAPc2 Phase 2b trial enrollment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000156459022035701/0001564590-22-035701-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000156459022035701/abio-8k_20221028.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-035701

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer